Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P0049: Bile acid profiling of ileal fluid in Crohn’s disease using metabolomicsECCO'25
Year: 2025
Authors: De Greef, I.(1)*;Loopmans, S.(2);Bislenghi, G.(3);D'Hoore, A.(3);Terrasson, I.(3);Verstockt, B.(4);Sabino, J.(4);Ferrante, M.(4);Ghesquière, B.(2);Vermeire, S.(4);Verstockt, S.(1);
(1)KU Leuven, Department of Chronic Diseases and Metabolism, Leuven, Belgium;(2)KU Leuven, Department of Cellular and Molecular Medicine, Leuven, Belgium;(3)University Hospitals Leuven, Department of Abdominal Surgery, Leuven, Belgium;(4)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;

(1) Vitek L. Bile acid malabsorption in inflammatory bowel disease. Inflamm Bowel Dis. 2015;21(2):476-83

P0050: 4-Octyl Itaconate Protects Against Colitis by Modulating Neutrophil Function and Enhancing Intestinal Epithelial Barrier IntegrityECCO'25
Year: 2025
Authors: Guo, M.(1)*;Lingjuan, J.(2);Ruan, G.(1);Runing, Z.(1);Yiqun, G.(3);Hong, Y.(1);
(1)Peking Union Medical College Hospital, Gastroenterology, Beijing, China;(2)Peking Union Medical College Hospital, Biomarker Discovery and Validation Facility, Beijing, China;(3)State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing Key Laboratory of Active Substance Discovery of Active Substances Discovery and Druggability Evaluation- Institute of Materia Medica- Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China;

1. Khor, B., A. Gardet and R. J. Xavier,Genetics and pathogenesis of inflammatory bowel disease[J]. Nature,2011,474(7351):307-317.
2. Graham, D. B. and R. J. Xavier,Pathway paradigms revealed from the genetics of inflammatory bowel disease[J]. Nature,2020,578(7796):527-539.
3. Kayama, H., R. Okumura and K. Takeda,Interaction Between the Microbiota, Epithelia, and Immune Cells in the Intestine[J]. Annu Rev Immunol,2020,38(23-48.
4. Fernandes, F. P., V. N. C. Leal, D. Souza de Lima, et al.,Inflammasome genetics and complex diseases: a comprehensive review[J]. Eur J Hum Genet,2020,28(10):1307-1321.
5. Wera, O., P. Lancellotti and C. Oury,The Dual Role of Neutrophils in Inflammatory Bowel Diseases[J]. J Clin Med,2016,5(12):
6. Boland, B. S., Z. He, M. S. Tsai, et al.,Heterogeneity and clonal relationships of adaptive immune cells in ulcerative colitis revealed by single-cell analyses[J]. Sci Immunol,2020,5(50):
7. Wang, F., F. Zhou, J. Peng, et al.,Macrophage Tim-3 maintains intestinal homeostasis in DSS-induced colitis by suppressing neutrophil necroptosis[J]. Redox Biol,2024,70(103072.
8. Kokkinou, E., T. Soini, R. V. Pandey, et al.,The single-cell transcriptional landscape of innate and adaptive lymphocytes in pediatric-onset colitis[J]. Cell Rep Med,2023,4(5):101038.
9. Garrido-Trigo, A., A. M. Corraliza, M. Veny, et al.,Macrophage and neutrophil heterogeneity at single-cell spatial resolution in human inflammatory bowel disease[J]. Nat Commun,2023,14(1):4506.
10. Minhas, P. S., A. Latif-Hernandez, M. R. McReynolds, et al.,Restoring metabolism of myeloid cells reverses cognitive decline in ageing[J]. Nature,2021,590(7844):122-128.
11. Michelucci, A., T. Cordes, J. Ghelfi, et al.,Immune-responsive gene 1 protein links metabolism to immunity by catalyzing itaconic acid production[J]. Proc Natl Acad Sci U S A,2013,110(19):7820-7825.
12. Ye, D., P. Wang, L. L. Chen, et al.,Itaconic acid in host inflammation and defense[J]. Trends Endocrinol Metab,2024,
13. Peace, C. G. and L. A. O'Neill,The role of itaconic acid in host defense and inflammation[J]. J Clin Invest,2022,132(2):
14. Selak, M. A., S. M. Armour, E. D. MacKenzie, et al.,Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase[J]. Cancer Cell,2005,7(1):77-85.
15. Tannahill, G. M., A. M. Curtis, J. Adamik, et al.,Succinate is an inflammatory signal that induces IL-1beta through HIF-1alpha[J]. Nature,2013,496(7444):238-242.
16. Mills, E. L., D. G. Ryan, H. A. Prag, et al.,Itaconic acid is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1[J]. Nature,2018,556(7699):113-117.
17. Bambouskova, M., L. Gorvel, V. Lampropoulou, et al.,Electrophilic properties of itaconic acid and derivatives regulate the IkappaBzeta-ATF3 inflammatory axis[J]. Nature,2018,556(7702):501-504.
18. Yang, W., Y. Wang, T. Wang, et al.,Protective effects of IRG1/itaconic acid on acute colitis through the inhibition of gasdermins-mediated pyroptosis and inflammation response[J]. Genes Dis,2023,10(4):1552-1563.
19. Harber, K. J., A. E. Neele, C. P. van Roomen, et al.,Targeting the ACOD1-itaconic acid axis stabilizes atherosclerotic plaques[J]. Redox Biol,2024,70(103054.
20. Zhang, X., Y. Zhi, X. Zan, et al.,Immune response gene 1 deficiency aggravates high fat diet-induced nonalcoholic fatty liver disease via promotion of redox-sensitive AKT suppression[J]. Biochim Biophys Acta Mol Basis Dis,2023,1869(4):166656.
21. Nair, S., J. P. Huynh, V. Lampropoulou, et al.,Irg1 expression in myeloid cells prevents immunopathology during M. tuberculosis infection[J]. J Exp Med,2018,215(4):1035-1045.
22. Frieler, R. A., T. M. Vigil, J. Song, et al.,Aconitate decarboxylase 1 regulates glucose homeostasis and obesity in mice[J]. Obesity (Silver Spring),2022,30(9):1818-1830.
23. Lampropoulou, V., A. Sergushichev, M. Bambouskova, et al.,Itaconic acid Links Inhibition of Succinate Dehydrogenase with Macrophage Metabolic Remodeling and Regulation of Inflammation[J]. Cell Metab,2016,24(1):158-166.
24. Cordes, T., M. Wallace, A. Michelucci, et al.,Immunoresponsive Gene 1 and Itaconic acid Inhibit Succinate Dehydrogenase to Modulate Intracellular Succinate Levels[J]. J Biol Chem,2016,291(27):14274-14284.
25. Sun, K. A., Y. Li, A. Y. Meliton, et al.,Endogenous itaconic acid is not required for particulate matter-induced NRF2 expression or inflammatory response[J]. Elife,2020,9(
26. Zeng, Y. R., J. B. Song, D. Wang, et al.,The immunometabolite itaconic acid stimulates OXGR1 to promote mucociliary clearance during the pulmonary innate immune response[J]. J Clin Invest,2023,133(6):
27. Weiss, J. M., E. M. Palmieri, M. Gonzalez-Cotto, et al.,Itaconic acid underpins hepatocyte lipid metabolism in non-alcoholic fatty liver disease in male mice[J]. Nat Metab,2023,5(6):981-995.
28. Odenwald, M. A. and J. R. Turner,The intestinal epithelial barrier: a therapeutic target?[J]. Nat Rev Gastroenterol Hepatol,2017,14(1):9-21.
29. Segui-Perez, C., D. A. C. Stapels, Z. Ma, et al.,MUC13 negatively regulates tight junction proteins and intestinal epithelial barrier integrity via protein kinase C[J]. J Cell Sci,2024,137(5):
30. Yao, Y., W. Shang, L. Bao, et al.,Epithelial-immune cell crosstalk for intestinal barrier homeostasis[J]. Eur J Immunol,2024,e2350631.
31. Mehandru, S. and J. F. Colombel,The intestinal barrier, an arbitrator turned provocateur in IBD[J]. Nat Rev Gastroenterol Hepatol,2021,18(2):83-84.
32. Firouzjaie, F., N. Taghipour, A. A. Akhavan, et al.,Neutrophil extracellular traps formation: effect of Leishmania major promastigotes and salivary gland homogenates of Phlebotomus papatasi in human neutrophil culture[J]. BMC Microbiol,2024,24(1):117.
33. Kang, L., X. Fang, Y. H. Song, et al.,Neutrophil-Epithelial Crosstalk During Intestinal Inflammation[J]. Cell Mol Gastroenterol Hepatol,2022,14(6):1257-1267.
34. Danne, C., J. Skerniskyte, B. Marteyn, et al.,Neutrophils: from IBD to the gut microbiota[J]. Nat Rev Gastroenterol Hepatol,2024,21(3):184-197.
35. Leppkes, M., A. Lindemann, S. Gosswein, et al.,Neutrophils prevent rectal bleeding in ulcerative colitis by peptidyl-arginine deiminase-4-dependent immunothrombosis[J]. Gut,2022,71(12):2414-2429..
36. Zhou, G., L. Yu, L. Fang, et al.,CD177(+) neutrophils as functionally activated neutrophils negatively regulate IBD[J]. Gut,2018,67(6):1052-1063.

P0051: Is NKCC1, a marker of dysplasia associated with inflammation and CAC, playing a role in colorectal carcinogenesis?ECCO'25
Year: 2025
Authors: Adam, P.(1)*;Salée, C.(1);Stepniak , M.(1);Loly, J.P.(2);Vieujean, S.(1,2,3);Reenaers , C.(2);Coimbra, C.(4);Decker, E.(4);Massot, C.(1,2);Delvenne, P.(5);Louis, E.(1,2);Meuwis, M.A.(1,2);
(1)GIGA institute Uliège, Laboratory of Translational Gastroenterology, Liège, Belgium;(2)CHU of Liège, Hepato-Gastroenterology and Digestive Oncology, Liège, Belgium;(3)INFINY Institute, Department of Gastroenterology INSERM NGERE, Nancy, France;(4)CHU of Liège, Abdominal- endocrine and transplantation, Liège, Belgium;(5)CHU of Liège, Pathological Anatomy and Cytology, Liège, Belgium;

1.          Fantini MC, Guadagni I. From inflammation to colitis-associated colorectal cancer in inflammatory bowel disease: Pathogenesis and impact of current therapies. Dig Liver Dis. 2021;53(5):558-565. doi:10.1016/j.dld.2021.01.012
2.          Merli AM, Vieujean S, Massot C, et al. Solute Carrier Family 12 Member 2 as a Proteomic and Histological Biomarker of Dysplasia and Neoplasia in Ulcerative Colitis. J Crohn’s Colitis. 2021;15(2):287-298. doi:10.1093/ecco-jcc/jjaa168
3.          Koumangoye R, Omer S, Kabeer MH, Delpire E. Novel Human NKCC1 Mutations Cause Defects in Goblet Cell Mucus Secretion and Chronic Inflammation. Cmgh. 2020;9(2):239-255. doi:10.1016/j.jcmgh.2019.10.006
4.          Pelka K, Hofree M, Chen JH, et al. Spatially organized multicellular immune hubs in human colorectal cancer. Cell. 2021;184(18):4734-4752.e20. doi:10.1016/j.cell.2021.08.003

P0052: Enhancing gut epithelial integrity and reducing epithelial inflammation through supplementation of fecal metabolites, guided by novel ex vivo functional prioritization and testingECCO'25
Year: 2025
Authors: Elwahidi , L.(1);Abbas-Egbariya , H.(1);Braun , T.(1);Amir , A.(1);Haberman , Y.(1)*;
(1)Sheba Medical Center, Department of Pediatric Gastroenterology, Ramat Gan, Israel;
P0053: Microscopic colitis: analysis of microbiota changes in different segments of the colon and terminal ileum.ECCO'25
Year: 2025
Authors: Kiudelis, V.(1,2)*;Alzbutas, G.(2);Karaliute, I.(2);Lukosevicius, R.(2);Berneriene, N.(2);Skieceviciene, J.(2);Kupcinskas, J.(1,2);
(1)Lithuanian University of Health Sciences, Department of Gastroenterology, Kaunas, Lithuania;(2)Lithuanian University of Health Sciences, Institute for Digestive Research, Kaunas, Lithuania;

​​1.Verhaegh BPM, Münch A, Guagnozzi D, et al. Course of Disease in Patients with Microscopic Colitis: A European Prospective Incident Cohort Study. J Crohns Colitis. 2021;15(7):1174-1183.
2.Miehlke S, Guagnozzi D, Zabana Y, et al. European guidelines on microscopic colitis: United European Gastroenterology (UEG) and European Microscopic Colitis Group (EMCG) statements and recommendations. United European Gastroenterol J. Published online 2020.
3.Burke KE, D’Amato M, Ng SC, Pardi DS, Ludvigsson JF, Khalili H. Microscopic colitis. Nat Rev Dis Primers. 2021;7(1). 

P0054: Human colonoid-derived monolayers and Caco-2: comparative analysis of inflammatory responsesECCO'25
Year: 2025
Authors: Chiara, M.L.(1)*;Parente, I.A.(1);Flammini, L.(1);Martina, V.(1);Vacondio, F.(1);Federica, G.(2);de’Angelis, G.L.(2);Elisabetta, B.(1);Bertoni, S.(1);
(1)University of Parma, Food and Drug Department, Parma, Italy;(2)University of Parma, Medicine and Surgery Department, Parma, Italy;
P0055: Impact of Indole-3-Propionic Acid on Bacterial Invasion Potential of Klebsiella Strains Isolated from Pediatric Ulcerative Colitis PatientsECCO'25
Year: 2025
Authors: Arjomand Fard, N.(1)*;Aujla, H.(2);Stuart, L.(1);C Cheng, C.(2);Elhenawy, W.(3);Perry, T.(4);Wine, E.(5);
(1)University of Alberta, Department of Physiology, Edmonton, Canada;(2)University of Alberta, Department of Pediatrics, Edmonton, Canada;(3)University of Alberta, Department of Medical Microbiology & Immunology, Edmonton, Canada;(4)University of Alberta, Department of Surgery, Edmonton, Canada;(5)University of Alberta, Department of Pediatrics and Physiology, Edmonton, Canada;

1. Ghiboub M, Verburgt CM, Sovran B, Benninga MA, de Jonge WJ, Van Limbergen JE. Nutritional therapy to modulate tryptophan metabolism and aryl hydrocarbon-receptor signaling activation in human diseases. Nutrients. 2020 Sep 17;12(9):2846.
2. Flannigan KL, Nieves KM, Szczepanski HE, Serra A, Lee JW, Alston LA, Ramay H, Mani S, Hirota SA. The pregnane X receptor and indole-3-propionic acid shape the intestinal mesenchyme to restrain inflammation and fibrosis. Cellular and molecular gastroenterology and hepatology. 2023 Jan 1;15(3):765-95.
3. Fu Y, Gao H, Hou X, Chen Y, Xu K. Pretreatment with IPA ameliorates colitis in mice: Colon transcriptome and fecal 16S amplicon profiling. Frontiers in Immunology. 2022 Sep 8;13:1014881.

P0056: Efficacy of Infliximab in Biologic-Experienced Patients with Inflammatory Bowel Disease: A Retrospective StudyECCO'25
Year: 2025
Authors: Borges Chaves, C.(1)*;Corveira, J.(2);Ferreira, A.M.(3);Lopes, S.(3);Mendes, S.(3);Ferreira, M.(3);Narra Figueiredo, P.(1,2);Portela, F.(2,3);
(1)Local Health Unit of Coimbra, Gastroenterology Department, Coimbra, Portugal;(2)University of Coimbra, Faculty of Medicine, Coimbra, Portugal;(3)Local Health Unit of Coimbra, IBD Unit- Gastroenterology Department, Coimbra, Portugal;

1. Grillo, S., Mezzina, N., Landi, S., Massari, A., Grassi, E., Dell’Era, A., & Ardizzone, S. (2018). P.07.22 Anti-TNF-Alfa Second-Line Infliximab Therapy in Patients Affected by Crohn’s Disease and Ulcerative Colitis: Who and How Recovers Remission? Digestive and Liver Disease: Official Journal of the Italian Society of Gastroenterology (SIGE) and of the Italian Association for the Study of the Liver (AISF), 50(2).

2. Russo E, Hackett R, Campbell S, et alPWE-071 Efficacy Of Infliximab As Second-line Biologic In Crohn’s DiseaseGut 2014;63:A154-A155.

P0057: METTL3 potentiates aged CD4+T cell response via programming effector differentiation in elderly ulcerative colitisECCO'25
Year: 2025
Authors: Zhang, Y.(1)*;Xu, J.(1);Cao, S.(1);Wang, J.(1);Lin, Y.(1);Liu, Y.(1);
(1)Peking University People's Hospital, Gastroenterology, Beijing, China;
P0058: Modulation of early innate and adaptive immune responses in primary human intestinal tissue ex vivoECCO'25
Year: 2025
Authors: Beneke, V.(1)*;Grieger, K.(1);Dehmel, S.(1);Neuhaus, V.(1);Linge, H.(2);Kulik, U.(2);Aselmann, H.(3);Gundert, B.(3);Braun, A.(1);Hesse, C.(1);Sewald, K.(1);
(1)Fraunhofer ITEM, Preclinical Pharmacology and Toxicology, Hannover, Germany;(2)Hannover Medical School MHH, Department of General- Visceral and Transplant Surgery, Hannover, Germany;(3)KRH clinics Hannover, Department of General- Visceral and Minimally Invasive Surgery, Hannover, Germany;
P0059: Mechanistic understanding of MB310: a consortium of gut commensal bacteria for the treatment of Ulcerative ColitisECCO'25
Year: 2025
Authors: Schreiber, F.(1)*;Villemin, C.(1);Sharpington, T.(2);Lawley, T.D.(2,3);Robinson , M.J.(4);Bakdash, G.(1);
(1)Microbiotica Ltd, Translational Biology, Cambridge, United Kingdom;(2)Microbiotica. Ltd, Microbiotica, Cambridge, United Kingdom;(3)Wellcome Sanger Institute, Host-Microbiota Interactions, Cambridge, United Kingdom;(4)Microbiotica Ltd, Discovery, Cambridge, United Kingdom;
P0060: GPR15L counteracts chronic colitis by shaping the intestinal microbiotaECCO'25
Year: 2025
Authors: Leggio, M.(1);Schramm, S.(1);Ocón, B.(2);Wirtz, S.(1);Puertolas Balint, F.(3);Dietz, L.(1);Schröder, B.(3);Butcher, E.(2);Müller, T.(1);Neurath, M.F.(1);Zundler, S.(1)*;
(1)University Hospital Erlangen, Department of Medicine 1, Erlangen, Germany;(2)Stanford University School of Medicine, Department of Pathology, Stanford, United States;(3)Umeå University, Department of Molecular Biology, Umeå, Sweden;
P0061: Guselkumab induction therapy results in molecular resolution of inflammation in moderately to severely active Ulcerative Colitis: results from the Phase 3 QUASAR induction studyECCO'25
Year: 2025
Authors: Sridhar, S.(1)*;Hart, A.(1);Venkat, S.(1);Huang, K.H.G.(1);Yarandi, S.(1);Germinaro, M.(1);Vetter, M.(1);Rubin, D.T.(2);Dignass, A.(3);Cua, D.(1);Freeman, T.(1);Waterworth, D.(1);McRae, B.(1);Verstockt, B.(4);Branigan, P.(1);
(1)Janssen Research & Development LLC, Research & Development, Spring House, United States;(2)University of Chicago Medicine- Inflammatory Bowel Disease Center, Medical, Chicago, United States;(3)Department of Medicine I, Agaplesion Markus Hospital- Goethe University, Frankfurt, Germany;(4)Department of Gastroenterology and Hepatology, University Hospitals Leuven- and Translational Research in Gastrointestinal Disorders- Department of Chronic Disease- Metabolism, Leuven, Belgium;

1.  Atreya R, Abreu MT, Krueger JG, et al. P165 Guselkumab binding to CD64+ IL-23–producing myeloid cells enhances potency for neutralizing IL-23 signaling. Journal of Crohn's and Colitis. 2024;18(Supplement_1):i470-i470. doi:10.1093/ecco-jcc/jjad212.0295
2.  The Efficacy and Safety of Guselkumab as Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Maintenance Study. Gastroenterol Hepatol (N Y). Jul 2024;20(7 Suppl 6):8-9.
3.  Peyrin-Biroulet L, Allegretti JR, Rubin DT, et al. Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study. Gastroenterology. Sep 1 2023;doi:10.1053/j.gastro.2023.08.038
4.  Sridhar S, Hart A, Venkat S, et al. OP23 Guselkumab induction restores intestinal immune homeostasis and promotes epithelial repair in moderately to severely active Ulcerative Colitis. Journal of Crohn's and Colitis. 2024;18(Supplement_1):i41-i41. doi:10.1093/ecco-jcc/jjad212.0023

P0062: Circulating immune cell populations as predictive markers of vedolizumab response in Crohn diseaseECCO'25
Year: 2025
Authors: Soleto, I.(1)*;González-de Castro, C.(2); Arribas, E.(3);Ramirez, C.(4);Baldan-Martin, M.(4); Riestra, S.(5); Lucendo, A.J.(6); García, M.J.(7); Martín-Arranz, E.(8);De Prado, Á.(3);Casanova, M.J.(4);Chaparro, M.(4);Bernardo*, D.(3);Gisbert*, J.P.(4);
(1)$Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-Princesa- Universidad Autónoma de Madrid UAM and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Inflammatory Bowel Disease Unit, Madrid, Spain;(2)$Unidad de Excelencia Instituto de Biomedicina y Genética Molecular IBGM- Universidad de Valladolid-CISC and Centro de Investigación Biomédica en Red de Enfermedades Infecciosas CIBERINFEC, Mucosal Immunology Lab, Valladolid, Spain;(3)Unidad de Excelencia Instituto de Biomedicina y Genética Molecular IBGM- Universidad de Valladolid-CISC and Centro de Investigación Biomédica en Red de Enfermedades Infecciosas CIBERINFEC, Mucosal Immunology Lab, Valladolid, Spain;(4)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-Princesa- Universidad Autónoma de Madrid UAM and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Inflammatory Bowel Disease Unit, Madrid, Spain;(5)Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias ISPA, Gastroenterology Unit, Oviedo, Spain;(6)Hospital General de Tomelloso- Instituto de Investigación Sanitaria de Castilla-La Mancha IDISCAM- CIBEREHD, Gastroenterology Unit, Ciudad Real, Spain;(7)Hospital Universitario Marqués de Valdecilla and IDIVAL, Gastroenterology and Hepatology Unit, Santander, Spain;(8)Hospital Universitario La Paz and Instituto de Investigación Sanitaria La Paz IdiPaz, Gastroenterology Unit, Madrid, Spain; *Authors share co-senior authorship. $ These authors contributed equally to this work
P0063: Prevalence of sarcopenia in a cohort of patients with inflammatory bowel disease: observational study in a tertiary care centreECCO'25
Year: 2025
Authors: Palmisano, C.M.(1)*;Dell'Aquila, P.(2);Cormio, S.(3);Boraccino, V.(4);Novielli, D.(4);Savino, F.(4);Squeo, F.(4);Forastiere, D.(4);Moschetta, A.(5);Principi, M.R.D.(6);
(1)University of Bari "Aldo Moro", Internal Medicine Unit "C. Frugoni" Department of Interdisciplinary Medicine-, Bari, Italy;(2)University of Bari, Department of Precision and Regenerative Medicine and Ionian Area, Bari, Italy;(3)University of Bari, Section of Gastroenterology- Department of Precision and Regenerative Medicine and Ionian Area-, Bari, Italy;(4)University of Bari, Section of Gastroenterology- Department of Precision and Regenerative Medicine and Ionian Area, Bari, Italy;(5)University of Bari, Department of Interdisciplinary Medicine- University of Bari "Aldo Moro", Bari, Italy;(6)University of Bari, 3 Section of Gastroenterology- Department of Precision and Regenerative Medicine and Ionian Area-, Bari, Italy;


  1. 2.      L.-K. Chen, L.-K. Liu, J. Woo, P. Assantachai, T.-W. Auyeung, K.S. Bahyah, et al. Sarcopenia in Asia: consensus report of the Asian working group for sarcopenia J Am Med Dir Assoc, 15 (2) (2014), pp. 95-101

    3. RA Fielding, B. Vellas, WJ Evans, S. Bhasin, JE Morley, AB Newman, et al. Sarcopenia: una condizione non diagnosticata negli anziani. Definizione di consenso attuale: prevalenza, eziologia e conseguenze. Gruppo di lavoro internazionale sulla sarcopenia J Am Med Dir Assoc, 12 (4) (2011), pagg. 249-256
P0064: Investigating a pathogenic role for IL-18 in Inflammatory Bowel Disease beyond the classical type 1 immunity paradigmECCO'25
Year: 2025
Authors: Grillmaier, M.(1)*;Barendregt, D.(1);Calado, B.(1);Heredia, M.(1);Smits, W.(1);Tuk, B.(1);van Berkel, L.(1);Hulleman-van Haaften, D.(1);Klomberg, R.(2);Vuijk, S.(2);Camman, A.(2);Doukas, M.(3);de Ridder, L.(2);Escher, J.(2);Samsom, J.(1);
(1)Erasmus University Medical Center - Sophia Children's Hospital, Laboratory of Pediatrics, Rotterdam, The Netherlands;(2)Erasmus University Medical Center - Sophia Children's Hospital, Pediatric Gastroenterology, Rotterdam, The Netherlands;(3)Erasmus University Medical Center, Pathology, Rotterdam, The Netherlands;
P0065: Circulating cell-free DNA and mitochondrial DNA differentiate disease activity in paediatric-onset inflammatory bowel disease: Interim analysis from Scotland-wide Mini-MUSIC study (2020-26)ECCO'25
Year: 2025
Authors: Wands, D.(1,2,3)*;Lau, S.Y.(2);Chuah, C.S.(2);Hall, R.(2);Whelan, R.(2);Fischer, L.(2);Kalla, R.(2);Cartlidge, P.(2);Drury, B.(2);Chalmers, I.(4);Hansen, R.(5);Wilson, M.(3);Jones, G.(2);Wilson, D.(3);Ho, G.T.(2);
(1)Royal Hospital For Children, Paediatric Gastroenterology- Hepatology and Nutrition, Glasgow, United Kingdom;(2)University of Edinburgh, Centre for Inflammation Research, Edinburgh, United Kingdom;(3)University of Edinburgh, Child Life and Health, Edinburgh, United Kingdom;(4)Royal Aberdeen Children’s Hospital, Department of Paediatric Gastroenterology- Hepatology and Nutrition, Aberdeen, United Kingdom;(5)University of Dundee, Division of Respiratory Medicine and Gastroenterology, Dundee, United Kingdom;

1. Haberman Y, Karns R, Dexheimer PJ, et al. Ulcerative colitis mucosal transcriptomes reveal mitochondriopathy and personalized mechanisms underlying disease severity and treatment response. Nat Commun. 2019;10(1):38. doi:10.1038/s41467-018-07841-32.       
2. Mottawea W, Chiang C-K, Mühlbauer M, et al. Altered intestinal microbiota-host mitochondria crosstalk in new onset Crohn’s  disease. Nat Commun. 2016;7:13419. doi:10.1038/ncomms134193.       
3. Chuah CS, Fischer L, Ho G-T. Circulating Cell-Free DNA in Inflammatory Bowel Disease: Liquid Biopsies with  Mechanistic and Translational Implications. Fac Rev. 2023;12:14. doi:10.12703/r/12-144.       
4. Boyapati RK, Dorward DA, Tamborska A, et al. Mitochondrial DNA Is a Pro-Inflammatory Damage-Associated Molecular Pattern Released During Active IBD. Inflamm Bowel Dis. 2018;24(10). doi:10.1093/ibd/izy095

P0066: Enhanced transcription of human endogenous retroviruses and downregulation of TRIM28 in patients with Crohn’s disease and ulcerative colitisECCO'25
Year: 2025
Authors: Ribaldone, D.G.(1)*;Bergallo, M.(2);Galliano, I.(2);Veglio, V.(3);Pitoni, D.(3);Caviglia, G.P.(3);Frara, S.(3);Anxhela, P.(3);Tribocco, E.(3);Tovo, P.A.(2);
(1)University of Turin, Department of Mediical Sciences, Turin, Italy;(2)University of Turin, Department of Public Health and Pediatric Sciences, Turin, Italy;(3)University of Turin, Department of Medical Sciences, Turin, Italy;
P0067: Exploring potential therapeutic implication of anti inflammatory drugs and Probiotic in Experimental Models of IBD-dependent SarcopeniaECCO'25
Year: 2025
Authors: Troisi , S.(1,2);Rondinone , B.(2);Petito , V.(2);Masi , L.(2);Emoli , V.(2);Deleu , S.(2,3,4);Pane , C.(1,2)*;Distante , S.(4);Lopetuso , L.R.(1,5,6);Gasbarrini , A.(2,4,6);Scaldaferri , F.(2,4,6);
(1)University of Chieti-Pescara ‘G. D’Annunzio’, Center for Advanced Studies and Technology CAST, Chieti, Italy;(2)Fondazione Policlinico Universitario “A. Gemelli”- IRCCS, CeMAD Translational Research Laboratory- Digestive Disease center- Department of Medical and Surgical Sciences, Rome, Italy;(3)KU Leuven, Department of Chronic Diseases & Metabolism CHROMETA, Leuven, Belgium;(4)Catholic University of the Sacred Heart, Department of Translational Medicine and Surgery, Rome, Italy;(5)University of Chieti-Pescara ‘G. D’Annunzio’, Department of Medicine and Ageing Sciences, Chieti, Italy;(6)Fondazione Policlinico Universitario “A. Gemelli” IRCCS, IBD unit- Digestive Disease center- Department of Medical and Surgical Sciences, Rome, Italy;

1. Dhaliwal A, Quinlan JI, Overthrow K, et al. Sarcopenia in Inflammatory Bowel Disease: A Narrative Overview. Nutrients. 2021;13(2):656. Published 2021 Feb 17. doi:10.3390/nu13020656
2. Ehlers L, Bannert K, Rohde S, et al. Preclinical insights into the gut-skeletal muscle axis in chronic gastrointestinal diseases. J Cell Mol Med. 2020;24(15):8304-8314. doi:10.1111/jcmm.15554
3. Neelam PB, Sharma A, Sharma V. Sarcopenia and frailty in inflammatory bowel disease: Emerging concepts and evidence. JGH Open. 2024;8(1):e13033. Published 2024 Jan 27. doi:10.1002/jgh3.13033

P0068: Distribution of α4β7 integrin and MAdCAM-1 expression according to the location of intestinal inflammation in a murine model of spontaneous chronic enterocolitisECCO'25
Year: 2025
Authors: Martinez Lozano, H.(1)*;Puerto Cantero, M.(2);Ruiz-Martín, C.(3);Miranda-Bautista, J.(1);Marín-Jiménez, I.(1);Menchén Viso, L.(1);
(1)Hospital General Universitario Gregorio Marañón, Gastroenterology, Madrid, Spain;(2)CIBEREHD-IISGM Instituto de Investigación Sanitaria Gregorio Marañón, Gastroenterology, Madrid, Spain;(3)IISGM Instituto de Investigación Sanitaria Gregorio Marañón, Gastroenterology, Madrid, Spain;